A drenergic signaling plays a fundamental role in regulating cardiac performance, and abnormalities in this pathway have been implicated as important determinants of diminished function of the failing heart. [1] [2] [3] [4] [5] The ␤ 1 -and ␤ 2 -adrenergic receptors (␤ARs), which bind circulating catecholamines, activate adenylyl cyclase by coupling through the stimulatory G-protein, G␣s. The resulting increase in intracellular cAMP activates cAMP-dependent protein kinase (PKA). In the inactive state, PKA exists as a tetramer, consisting of two regulatory and two catalytic subunits. 6 Binding of cAMP by the regulatory subunits results in their dissociation from the catalytic subunits and activation of the enzyme. Thus, increasing the ratio of catalytic to regulatory subunits is sufficient to activate PKA. 7 PKA has several substrates in cardiomyocytes that influence contractility in response to activated ␤AR signaling; these include the L-type Ca 2ϩ channel in the sarcolemma, the ryanodine receptor (RyR2), and phospholamban in the sarcoplasmic reticulum (SR). Phosphorylation of phospholamban (PLB) leads to the increased activity of the sarcoplasmic reticulum Ca 2ϩ -ATPase (SERCA) and consequent accelerated Ca 2ϩ accumulation in the SR. This increases the SR Ca 2ϩ content available for subsequent cardiac cycles and thereby increases contractility. PKA also phosphorylates the RyR2, the Ca 2ϩ -release channel in the SR, resulting in dissociation of the Ca 2ϩ channel regulator FKBP12.6 and consequent increase in Ca 2ϩ sensitivity for channel activation. 8 PKA phosphorylation of the RyR2 is markedly increased in failing human hearts, 8 suggesting a link between PKA signaling and altered inotropy associated with long-term ␤AR signaling.
Chronic heart failure is associated with an increase in circulating catecholamines. 9 Prolonged ␤AR stimulation results in the uncoupling of ␤ARs from downstream effectors through 2 mechanisms: downregulation of receptor number (␤ 1 ) 10 and desensitization of the receptors (␤ 2 ). 1, 10 Although the mechanisms regulating the loss of ␤ 1 -AR number are not clear, ␤ 2 -AR desensitization results from phosphorylation of the cytoplasmic domain of the receptor by ␤AR kinase (␤ARK). 11 ␤ARK is upregulated in the failing heart, which has been proposed as a mechanism to account for diminished ␤AR responsiveness. [12] [13] [14] Consistent with this notion, ␤ARK inhibitors increase cardiac contractility in vivo. 15,16 ␤ 2 -ARs are also phosphorylated by PKA, 17, 18 which results in diminished ␤AR activity and implicates PKA in impaired cardiac contractility.
Several transgenic mouse models have addressed the roles of ␤AR/adenylyl cyclase signaling in cardiac function. Increased transgenic expression of the ␤ 1 -AR in the heart initially increases contractility, 19 but its chronic activity leads to decreased function and eventual cardiac failure. 19, 20 Simi-larly, transgenic cardiac overexpression of G␣s in mice causes cardiomyopathy due to sustained activation of the ␤AR pathway. In contrast, chronic cardiac adenylyl cyclase activity (which is activated by Gs␣) has been shown to result in long-term enhanced function, 21, 22 and in transgenic mouse models that suffer from cardiac failure, the overexpression of adenylyl cyclase improves contractility. 23 These data indicate that components of the ␤-adrenergic signaling pathway may have different consequences on cardiac performance.
Despite extensive investigations into the role of ␤AR/ adenylyl cyclase signaling in the heart, it is unknown whether PKA activation alone is sufficient to evoke pathological changes in cardiac function associated with chronic ␤AR stimulation or to ameliorate cardiomyopathic stimuli as attributed to overexpression of adenylyl cyclase. To investigate the role of cardiac PKA signaling in the absence of other ␤AR-dependent signaling events, we generated transgenic mice that overexpressed the PKA catalytic subunit under control of the ␣-myosin heavy chain (␣-MHC) promoter. These mice developed profound chamber dilation, with decreased cardiac function, edema, arrhythmias, and susceptibility to sudden death. Cardiac RyR2 and PLB were hyperphosphorylated in PKA transgenic mice, consistent with the notion that they mediate the effects of PKA on cardiac contractility. Our data demonstrate that upregulated PKA activity is detrimental to cardiac physiology and suggest a role for hyperphosphorylation of PKA targets in the pathogenesis of dilated cardiomyopathy.
Materials and Methods

Generation of Transgenic Mice
A cDNA encoding the PKA-C␣ subunit was cloned 3Ј to the ␣-MHC promoter and 5Ј to the human growth hormone poly A ϩ signal. DNA isolation and oocyte injections were performed as described. 24 Genomic DNA was isolated from mouse tail samples and was analyzed by Southern blot with a probe for the human growth hormone 3Ј region. Mice were obtained from the National Cancer Institute, Frederick, Md.
PKA Enzyme Assay
PKA activity of transgenic and wild-type ventricular samples was determined by measuring ␥ 32 P incorporation into a biotinylated substrate (LRRASLG) using the SignaSECT cAMP-dependent protein kinase (PKA) assay system (Promega).
RNA Analysis
Total RNA was obtained from ventricular tissue using Trizol Reagent (Roche). Dot blot analysis was performed as described. 25 
Histology
Hearts were isolated, incubated in Krebs-Hanseleit solution lacking Ca 2ϩ to relax the cardiac muscle, and fixed (10% formalin) overnight at 4°C. Samples were dehydrated, mounted in paraffin, and sectioned (10 m thickness). The sections were stained with either eosin and hematoxylin dyes to determine cell and nuclear size or Massontrichrome dye to visualize collagen deposits (fibrosis) in the ventricular and septal walls.
Transthoracic Echocardiography
Cardiac function of control and transgenic mice aged 8 to 10 weeks was evaluated with echocardiography. Echocardiography was performed on anesthetized mice (2.5% Avertin-15 L/g body weight) using a Hewlett Packard Sonos 5500 Ultrasound system with a 12
Mhz transducer. Heart rates were determined by ECG analysis. Three independent M-mode measurements per animal were obtained. End-systolic and end-diastolic chamber diameters, interventricular septum and posterior wall thicknesses, as well as left ventricular fractional shortening (FS% ϭ [(LVEDD-LVESD)/ LVEDD]ϫ100) were determined in a short-axis view at the level of the papillary muscles. Animal handling was performed according to UT Southwestern Institutional guidelines.
Immunoprecipitation and BackPhosphorylation Assays
Heart homogenates were prepared and immunoprecipitation assays were performed as previously described. 8 
Western Blots
Heart homogenates were immunoprecipitated with anti-RyR (5029) antibody and samples were size fractionated by SDS-PAGE. Separated proteins were transferred to nitrocellulose membranes and Western blots were performed using anti-RyR and anti-FKBP antibodies. 26 To quantify phospholamban phosphorylation, 50 g protein from heart homogenates were size fractionated by SDS-PAGE on a 15% gel and immunoblotted with a phospholamban phosphoepitope specific antibody (1:5000 dilution, PS-16, Cyclcel Ltd).
Single Channel Recordings
RyR2 single channel recordings under voltage-clamp conditions were performed and analyzed as described. 27 At the conclusion of each experiment, ryanodine and/or ruthenium red were applied to demonstrate the identity of RyR2 channels. Results are meanϮstandard deviation; the Student's t test was used for statistical analyses.
Results
Generation of ␣MHC-PKA-Transgenic Mice
To study the effects of chronic PKA activation in the adult heart, we generated transgenic mice with a transgene encoding the catalytic subunit of PKA under control of the ␣MHC promoter. Two independent transgenic lines were generated with 1 and 3 copies of the transgene, as determined by Southern analysis of genomic DNA (data not shown).
Because the level of PKA activity is determined by the ratio of catalytic and regulatory subunits, overexpression of the catalytic subunit results in constitutive activation of the enzyme without a requirement for cAMP. Assays for PKA activity in mouse heart extracts confirmed that PKA activity was elevated 2.4-fold (line-33) and 8-fold (line-2) in the 2 transgenic lines (Figure 1) . A third founder harboring the ␣MHC-PKA transgene died with a dilated heart at 17 weeks.
Cardiomyocyte Hypertrophy in ␣MHC-PKA-Transgenic Mice
Hearts from younger (4 to 8 weeks old) PKA-transgenic mice appeared normal. PKA-transgenics 10 weeks and older showed a slight increase in heart-to-body-weight ratios (Figure 1B) . Histological analysis showed that the ventricular walls of the PKA transgenic mice were only moderately thicker at 10 weeks of age ( Figure 2A ). However, individual cardiomyocytes from PKA-transgenic mice were significantly enlarged ( Figure 2A ). The average cross-sectional area of cardiomyocytes from papillary and peripheral regions of the ventricles was 3.5Ϯ0.9ϫ10 2 m 2 in PKA-transgenics compared with 2.5Ϯ0.6ϫ10 2 m 2 (PϽ0.01) in wild-type mice. There was also an increase in cardiomyocyte nuclear dimensions in PKA-transgenic animals. The average crosssectional area of cardiomyocyte nuclei from PKA-transgenic mice was 2.5Ϯ0.6ϫ10
Ϫ1 m 2 compared with 1.5Ϯ0.7ϫ10 Ϫ1 m 2 from wild-type siblings (PϽ0.005). PKA overexpression resulted in elevated expression of the hypertrophic marker genes ANF and ␤-MHC. Conversely, transcripts for SERCA2, PLB, and ␣-MHC were downregulated in hearts from PKA-transgenic mice, as seen in human heart failure 28 ( Figure 2B ).
␣MHC-PKA-Transgenic Mice Develop Dilated Cardiomyopathy
By 13 weeks of age, transgenic animals typically developed enlarged hearts ( Figure 3A) . Histological sections showed that the PKA-induced enlargement was a result of cardiac dilation ( Figure 3B ). The dilated hearts showed mild fibrosis, which contrasts with the extensive amounts of fibrotic scar tissue that result from continual ␤-adrenergic stimulation. 29 PKA-transgenic mice also displayed symptoms indicative of congestive heart failure: the atria of transgenic mice frequently contained organized thrombi ( Figure 3C , arrows) and, in particularly severe cases, transgenic animals also developed edema ( Figure 3D ). In accordance with the pathology, PKA-transgenic animals displayed higher mortality (Figure 4) . The increased frequency of death correlated with the amount of PKA activity: the activity of transgenic line-2 was greater than that of transgenic line-33 ( Figure 4 ).
Impaired Contractility in ␣MHC-PKATransgenic Mice
In order to examine the effect of PKA overexpression before the onset of dilated cardiomyopathy, in vivo cardiac morphology and performance were analyzed by echocardiography at 8 weeks of age. PKA-transgenic animals displayed increased systolic dimensions (PϽ0.04) and a tendency toward in- 
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Physiological Consequences of Long-Term PKA Activation 999 creased diastolic diameters of the left-ventricular chamber (Table) . Fractional shortening was significantly reduced in PKA-transgenic animals, indicating contractile dysfunction (27.0% versus 42.5%, PϽ0.005) (Table) . In contrast to regular sinus rhythm in wild-type siblings ( Figure 5A ), ECG-analysis during echocardiography revealed atrial fibrillation in 5 of 8 transgenic animals ( Figure 5B ). Transgenic animals frequently exhibited premature ventricular beats, suggesting a susceptibility to ventricular arrhythmias. In one severe case, spontaneous pauses in contraction lasting longer than 5 seconds were observed ( Figure 5C ), which likely were the consequence of intermittent higher degree sinoatrial block. PKA-transgenic animals also displayed a statistically significant decrease in heart rate (Table) . M-mode echocardiography showed that 8-week-old PKA transgenic animals did not suffer from gross hypertrophy of the cardiac wall. The thicknesses of the septal and posterior walls of the hearts, as determined by echocardiography, were comparable in wild-type and transgenic animals during diastole and systole (Table) .
Hyperphosphorylation of the RyR2 and PLB in PKA-Transgenic Mice
Because PKA phosphorylation of RyR2 and PLB can alter cardiac physiology, we compared the phosphorylation status of these molecules in PKA-transgenic and wild-type mice. To determine the endogenous phosphorylation status of the RyR2, we performed back-phosphorylation assays. As shown in Figure 7 , RyR2 from wild-type hearts was efficiently phosphorylated in vitro. In contrast, less 32 P incorporation was detected in the RyR2 from hearts of PKA-transgenics. The level of 32 P incorporation onto RyR2 in vitro is inversely proportional to the extent of phosphorylation of the proteins in vivo. Comparison of the 32 P incorporation on RyR2 indicates a 3.5-fold increase in PKA phosphorylation of RyR2 from the PKA-transgenic heart lysates compared with wild-type controls in vivo ( Figures 6A and 6B, PϽ0.01) .
PLB is phosphorylated by PKA on serine-16, a site that is specific for PKA activity. Immunoblots using an antibody specific for PKA-phosphorylated PLB showed that phosphorylation of serine-16 was increased 4-fold in the hearts of Assessment of ventricular function of wild-type and PKA-transgenic mice (line-2). Measurements are from interventricular septum (IVS), chamber (LVED), and posterior wall (LVPW) during distole and systole, respectively, in wild-type (nϭ5) and transgenic siblings (nϭ8). Fractional shortening values of wild-type and PKA-transgenic mice, calculated from LVEDD and LVESD measurements, show that PKA overexpression results in reduced cardiac function in 8-weekold transgenic mice. Also, PKA-transgenic animals displayed a reduced average heart rate during phases of continuous contractions. *PϽ0.005, †PϽ0.002, ‡PϽ0.04. PKA-transgenic mice compared with wild-type littermate controls ( Figure 6C, nϭ3, PϽ0.01) .
Measurements From M-Mode Echocardiography
The open probability (P o ) of RyR2 is decreased by the interaction of the RyR2 with FKBP12.6, a cis-trans peptidylprolyl isomerase that is expressed in cardiac muscle. 30 In order to determine whether hyperphosphorylation of the RyR2 stoichiometrically altered the interaction between RyR2 and FKBP12.6, we performed coimmunoprecipitation experiments with RyR2. These experiments showed a 60% decrease in the amount of FKBP12.6 in the RyR2 macromolecular complex in PKA-transgenic hearts ( Figure 7A , nϭ4, PϽ0.01). As shown to occur in human heart failure, dissociation of FKBP12.6 from the channel results in increased P o for the RyR2 channels. 8 Similarly, the P o of RyR2 in PKA-transgenic mouse hearts was 10-fold greater than that in wild-type mouse hearts ( Figure 7B , P o ϭ0.05Ϯ0.003 to P o ϭ0.004Ϯ0.001, nϭ6, PϽ0.01).
These results show that the PKA sites in the RyR2 and PLB are hyperphosphorylated in PKA-transgenic mice and are substoichiometrically phosphorylated in the hearts of wild-type animals. Furthermore, these events are associated with increased RyR2 activity, which suggests that the dysfunctional physiology suffered by PKA-transgenic mice results from reduced cardiac performance due to altered Ca 2ϩ fluxes.
Discussion
Heart failure is associated with diminished ␤AR responsiveness, loss of cardiac contractility, and abnormalities in Ca 2ϩ -handling. 2,31,32 ␤-Adrenergic stimulation modulates Ca 2ϩ fluxes and Ca 2ϩ responsiveness of the sarcomere, which links ␤-adrenergic signaling to contractility. Whereas short-term activity of the ␤AR pathway increases inotropy/chronotropy, chronic ␤AR activation is maladaptive. 33 Transgenic mice that overexpress ␤ARs or Gs␣ in the heart ultimately develop dilated cardiomyopathy. 19,20,34 -36 Intriguingly, activation of different ␤ARs can lead to different outcomes on the heart. Chronic elevation of the ␤ 1 -AR produces a pathological phenotype within a few months. 19, 20 Unless active at very high levels, ␤ 2 -AR signaling results in a prolonged increase in inotropy and chronotropy without cardiomyocyte toxicity. 36 Active ␤AR or Gs␣ increases basal adenylyl cyclase activity, 36 -39 but extended transgenic overexpression of adenylyl cyclases does not reproduce any pathology. 21, 22 Because of . PKA hyperphosphorylation of RyR2 and PLB. A, RyR2 was immunoprecipitated from 4-week-old PKA-transgenic (line-2) and wild-type mouse hearts and back-phosphorylated with PKA (upper panel). The PKA inhibitor, PKI was used to demonstrate specificity of PKA phosphorylation. Immunoblot (lower panel) shows equal amounts of immunoprecipitated RyR2. B, PKA phosphorylation of RyR2 was quantified using densitometry and normalized for the amount of RyR2 immunoprecipitated in each sample, respectively, and expressed as the inverse of the back-phosphorylation. The number of mice analyzed of each genotype were as follows: WT, nϭ5; line-33, nϭ3; line-2, nϭ4. C, PLB phosphorylation was assessed using a phosphoepitope specific antibody that recognizes the phosphorylated serine-16 on PLB. A representative immunoblot (inset, upper panel) and the bar graph (lower panel) shows the quantification of results from 2 separate experiments from three transgenic (line-2) and 3 wild-type hearts.
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Physiological Consequences of Long-Term PKA Activationthese results and the fact that downregulation of the ␤AR is coupled with heart failure, it is unclear which of the effects of this signaling system are mediated by PKA activation and which reflect alterations in ␤AR-adenylyl cyclase coupling or other early events associated with ␤AR occupancy. 40 , 41 Our results demonstrate that prolonged activation of PKA in the heart results in dilated cardiomyopathy, arrhythmias, and sudden death, which accompany hyperphosphorylation of RyR2 and PLB.
Hyperphosphorylation of RyR2 and PLB in Response to PKA
Heart failure is associated with alterations in excitationcontraction coupling, which are dependent on release and uptake of Ca 2ϩ from and into the SR. 32 The RyR2 mediates Ca 2ϩ release from the SR. Entry of Ca 2ϩ into cardiomyocytes via the voltage-gated L-type Ca 2ϩ channel triggers activation of RyR2 during each cardiac action potential: an event known as Ca 2ϩ -induced Ca 2ϩ release. 42 RyR2 is localized to the SR and is the primary regulator of the Ca 2ϩ signal that induces contraction. RyR2 is part of a large macromolecular complex that includes PKA, the protein phosphatases PP1 and PP2A, and the FK-506 -binding protein FKBP12.6. 8 PKA phosphorylates serine 2809 on the cytoplasmic surface of the RyR2, which results in dissociation of FKBP12.6 from RyR2. FKBP12.6, is required for normal gating of the Ca 2ϩ channel, 30 so the consequence of dissociation is an increase in Ca 2ϩ sensitivity for channel activation. 8 Recent studies have shown that the PKA site on the RyR2 is also hyperphosphorylated in failing human hearts and that treatment with a left ventricular assist device, which restores cardiac function, is accompanied by a reduction in RyR2 phosphorylation by PKA to normal levels. 8 This association of RyR2 hyperphosphorylation with heart failure suggests that negative regulation of the RyR2 is an effector of heart failure. Chronic RyR2 activation and FKBP12.6 depletion can lead to a leftward shift of Ca 2ϩ -dependent activation and a reduction in coupled gating of the RyR2. 8 This may lead to a diastolic leak of SR Ca 2ϩ , contributing to diastolic dysfunction as is frequently observed in heart failure patients. The demonstration of PKA-hyperphosphorylation of RyR2, FKBP12.6 depletion, and increased P o of the channels from the PKA-transgenic hearts suggests that altered regulation of SR Ca 2ϩ release may play a role in heart failure and arrhythmias observed in these mice. The PKA-hyperphosphorylated channels would be predicted to be more active at low cytosolic [Ca 2ϩ ] as previously reported for RyR2 channels from failing human and canine failing hearts. 8 This increased activity is due to increased sensitivity to Ca 2ϩ -induced Ca 2ϩ release. 8 Furthermore, diastolic Ca 2ϩ release could provide a stimulus to remove the excess Ca 2ϩ via the Na ϩ -Ca 2ϩ exchanger in the sarcolemma. This would eventually lead to a depletion of SR Ca 2ϩ , making it unavailable for subsequent release during systole and ultimately resulting in a deterioration of systolic performance. Moreover, activation of reverse mode Na ϩ -Ca 2ϩ exchange can result in inward depolarizing currents leading to delayed after-depolarizations that could trigger arrhythmias.
Uptake of Ca 2ϩ into the SR is mediated by SERCA2a, which is negatively regulated by PLB. Phosphorylation of PLB relaxes its inhibitory effects on SERCA2a, which results in an increased removal of Ca 2ϩ from the sarcoplasm by SERCA2a after ␤-adrenergic stimulation. [43] [44] [45] Loss of PLB has been reported to ameliorate the heart failure phenotype in mice lacking the muscle LIM-domain protein, MLP. 46 This suggests that inactivation of PLB via PKA phosphorylation is beneficial. Yet, despite PLB hyperphosphorylation, PKAtransgenic animals developed dilated cardiomyopathy. We propose that the chronic activity of RyR2 (which would cause a leak of SR Ca 2ϩ ) predominates over any benefit conveyed by inactivation of PLB. Sustained depletion of Ca 2ϩ from the SR and its removal from the cardiomyocyte may gradually render any positive effect of increased SERCA2a activity inconsequential.
Signals for Altered Physiology and Dilated Cardiomyopathy
The dilated cardiomyopathy, depressed cardiac contractility and increased frequency of arrhythmias of PKA-transgenic mice is reminiscent of the pathophysiology of ␤ 1 -AR-and Gs␣-overexpressing mice. Interestingly, chronic PKA overexpression in the heart results in reduced heart rate, whereas chronic Gs␣-overexpression results in increased heart rate. 35 This could suggest the activation of different effectors even though both Gs␣ and PKA are involved in ␤AR signal transduction.
Chronic ␤AR activation stimulates multiple signaling events and ultimately leads to dilated cardiomyopathy. 33 However, experiments in which adenylyl cyclases are over- shows that equal amounts of RyR2 were immunoprecipitated using antiRyR2 antibody (5029). FKBP12.6 was coimmunoprecipitated with RyR2 (lower panel). B, Microsomes containing RyR2 were isolated from 4-week-old PKA-transgenic mice (line-2) and from wild-type mouse hearts and incorporated into planar lipid bilayers. The cis (cytosolic) [Ca 2ϩ ] was 150 nmol/L. Channel openings are upward; "c" denotes the closed state of the channels. Note that the time scale is expanded in the bottom 2 tracings. expressed in the heart have indicated that activation of certain downstream components of ␤-adrenergic signaling does not result in failure. Adenylyl cyclase overexpression results in improved performance without the pathological consequences of continuous ␤AR stimulation. 21, 22 Yet, one study found increased PKA activity in the cardiomyopathic hamster UM-X7, which implicates the involvement of PKA activity in the generation of cardiomyopathy. 47 Although increased expression of adenylyl cyclases may be beneficial, our data indicate that increased activity of PKA in the heart is not, so understanding the difference between adenylyl cyclase signaling and PKA signaling may be crucial for elucidating the difference between compensatory and decompensatory cardiac physiology. One possibility is that adenylyl cyclases may interact with other factors that buffer the deleterious effects of sustained, high levels of PKA enzymatic activity. In this respect, PKA phosphorylates adenylyl cyclase isoforms that are present in cardiomyocytes, which reduces adenylyl cyclase activity 48, 49 and, thereby, may attenuate any beneficial effects conveyed by adenylyl cyclase signaling.
There is growing evidence that ␤-adrenergic signaling is spatially regulated. ␤ARs appear to be localized to distinct regions of the plasma membrane. 50 Further intracellular compartmentalization of ␤-adrenergic signaling is achieved through A-kinase anchoring proteins (AKAPs) that confine PKA activity. 51 PKA is targeted to the RyR2 via mAKAP. 8 Thus, although global PKA activity appears to be unchanged in myocardial tissue of patients suffering from dilated cardiomyopathy, 52, 53 site-or substrate-specific signaling by PKA may contribute to the progression of heart failure.
Our results indicate that PKA is a key mediator of the deleterious effects of chronic ␤AR signaling and that exacerbated PKA activity selectively results in dilated cardiomyopathy. This suggests that chronic phosphorylation of PKA substrates including RyR2 is associated with dilation and failure. Furthermore, the diminished contractility, arrhythmias, histological changes, and susceptibility to sudden death in PKA-transgenic mice resemble the clinical picture of human dilated cardiomyopathy. It is likely that the sustained pleotrophic effect of deregulated Ca 2ϩ fluxes and deregulated Ca 2ϩ utilization due to PKA activity causes the progression to heart failure. Taken together, PKA-transgenic mice represent a model for further exploring the downstream consequences of chronic ␤-adrenergic signaling and dilated cardiomyopathy.
